Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.64 |
| ▸ | MEN1 | O00255 | 7/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | TYMS | P04818 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | CASP6 | P55212 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | S100B | P04271 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14172750 | 0.93 | KMT2A (0.72) | KMT2AMEN1ALDH1A1KDM4ETYMS | |
| SCHEMBL16602052 | 0.87 | KMT2A (0.70) | KMT2AMEN1ALDH1A1KDM4ETYMS | |
| SCHEMBL14510327 | 0.86 | KMT2A (0.64) | KMT2AMEN1ALDH1A1KDM4ETYMS | |
| SCHEMBL5160880 | 0.84 | KMT2A (0.63) | KMT2AMEN1ALDH1A1KDM4ETYMS | |
| SCHEMBL5160901 | 0.84 | KMT2A (0.63) | KMT2AMEN1ALDH1A1KDM4ETYMS | |
| SCHEMBL1514286 | 0.82 | L3MBTL1 (0.73) | KMT2AMEN1ALDH1A1KDM4ETYMS | |
| SCHEMBL4230581 | 0.82 | S100B (0.74) | KMT2AMEN1ALDH1A1KDM4ETYMS | |
| SCHEMBL7825377 | 0.82 | TYMS (0.71) | KMT2AMEN1ALDH1A1KDM4ETYMS | |
| SCHEMBL29549557 | 0.82 | TYMS (0.71) | KMT2AMEN1ALDH1A1KDM4ETYMS | |
| SCHEMBL18201564 | 0.81 | NPC1 (0.69) | KMT2AMEN1ALDH1A1KDM4ETYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931664-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2008-06-18 | — | — | EP | claimed |
| US-7279580-B2 | Imidazo-pyridine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-09 | — | — | US | claimed |
| US-20070099900-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-03 | — | — | US | claimed |
| WO-2007030934-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | claimed |
| US-7279580-B2 | Imidazo-pyridine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20070099900-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-03 | — | — | US | disclosed |
| US-20070099900-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-03 | — | — | US | disclosed |
| US-20070099900-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-03 | — | — | US | disclosed |
| WO-2007030934-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | disclosed |
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099900-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | KMT2A 4267/4885MEN1 3865/4885ALDH1A1 2086/4885 |
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | GABRA3, GABRA2, GABRA5 | KMT2A 1066/4885MEN1 4452/4885ALDH1A1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.